Last year did a lot to crush my usually optimistic outlook on the future. I experienced a level of cynicism I haven’t felt since high school, a time when I only ever assumed things would get worse and rarely made an effort to change that. It was bad. Global pandemics have that effect on people.
I still made it a point to note when positive things actually happened, especially when it came to news of the vaccine. That marked the ultimate turning point. A vaccine was always going to be our best weapon in terms of ending the pandemic, regardless of what the anti-vaxx crowd says. The fact that we now have two vaccines at our disposal is genuinely encouraging.
Yes, I know the distribution of these vaccines has been a mess, to say the least.
I also don’t deny that the emergence of new mutant strains of the virus could hinder their effectiveness.
Those are legitimate concerns. We should all be worried about how this will impact our ability to finally end this awful pandemic that has caused so much damage. At the same time, we should also be hopeful. Believe me, I’m trying.
That hope got another boost recently when it was announced that a third vaccine developed by Johnson & Johnson had completed its final round of trials. Having a third weapon against this virus can only help. In addition, this one has the advantage of being a one-shot vaccine, as opposed to the two required by Moderna and Pfizer.
While that’s good news for those who hate needles, there is a trade-off. According to the research reported by the media, the vaccine is effective. However, the numbers aren’t quite as promising as what we got with the first two. This is what CNN reported.
CNN: Johnson & Johnson Covid-19 vaccine is 66% effective in global trial, but 85% effective against severe disease, company says
Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease, the company announced Friday.
The vaccine was 72% effective against moderate and severe disease in the US, the company said.
It’s a striking difference from vaccines from Pfizer/BioNTech and Moderna, and it may give pause to people uncertain about which vaccine to get or when they can get one. The vaccines already on the market in the US are about 95% effective overall against symptomatic Covid-19, with perhaps even higher efficacy against severe cases.
But experts say the Johnson & Johnson vaccine will still be useful against the pandemic in the United States and around the world.
I know the numbers are the only thing that stands out in this piece. That seems to be the main sticking point for most reports about this virus.
Those numbers are still good. The 66% may not be as promising as the 90% promised by the other two, but that’s still more effective than a standard flu vaccine. On top of that, being a one-shot vaccine that can be easily stored in a typical refrigerator will help even more. It means more of this vaccine can get to people, especially in places with less-than-ideal health infrastructure.
This will definitely help in terms of ending or at least mitigating this pandemic. However, there’s one other critical point of data that’s worth highlighting with this vaccine. It’s in some of the reports, but it’s often difficult to discern, mostly because the media’s track record with reporting science is not that great.
For this vaccine, it’s boils down to certain degrees within the data. It’s true the Johnson & Johnson vaccine won’t give you the same protection you’d get from the other two. There’s a good chance that, even after getting this vaccine, you could still become very sick with COVID-19. However, and this is the key, it will help ensure that you don’t become severely ill and die.
That’s not just a sales pitch. According to the research, there were no hospitalizations or deaths among people in the vaccine arm. That may mean some did get sick. Some might have even spread it. However, they didn’t get so sick that they ended up in the hospital. They all survived.
To me, at least, that’s the most important result. Getting sick is one thing. Getting so sick that you die in a hospital bed is something else entirely. One is a bad flu. The other is debilitating illness. That alone makes this vaccine a critical tool in the effort to end this pandemic.
I admit that if I had a choice between the three, I would choose Moderna or Pfizer. I actually know someone who got the Pfizer vaccine and their experience gives me great assurance that it works as intended.
However, if those two were not available and all I could get was the Johnson & Johnson vaccine, I’d take it in a heartbeat. It could mean the difference between being sick and being deathly ill. In a pandemic, that’s the only difference that matters. To all the doctors, nurses, participants, and health care workers who were part of this effort, I sincerely thank you. A lot of lives will be saved because of this vaccine. That makes you true heroes in a world that badly needs them.
One response to “Vaccine Update: Making Sense Of The (Critical) Data On The Johnson & Johnson Vaccine”
Pingback: I’m Officially Vaccinated! Please Do The Same | Jack Fisher's Official Publishing Blog